Rui Cheng Selected Research

Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain)

4/2024	The current clinical landscape of neonatal respiratory failure in Jiangsu Province of China: patient demographics, NICU treatment interventions, and patient outcomes.
1/2022	The effect of erythropoietin on neonatal hypoxic-ischemic encephalopathy: An updated meta-analysis of randomized control trials.
1/2015	MicroRNA-210 knockdown contributes to apoptosis caused by oxygen glucose deprivation in PC12 cells.
6/2013	Neuroprotective effects of microRNA-210 against oxygen-glucose deprivation through inhibition of apoptosis in PC12 cells.
1/2013	Neuroprotective effects of microRNA-210 on hypoxic-ischemic encephalopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rui Cheng Research Topics

Disease

39	Neoplasms (Cancer) 03/2024 - 04/2006
16	Bronchopulmonary Dysplasia 03/2024 - 01/2018
15	Inflammation (Inflammations) 01/2024 - 04/2013
10	Birth Weight (Birth Weights) 04/2024 - 01/2013
9	Hypoxia (Hypoxemia) 01/2020 - 10/2007
9	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2019 - 09/2013
8	Apnea 11/2022 - 12/2018
7	Infections 03/2024 - 08/2017
6	Patent Ductus Arteriosus 04/2024 - 05/2012
6	Hemorrhage 01/2024 - 05/2012
6	Pain (Aches) 01/2020 - 05/2012
5	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 04/2024 - 01/2013
5	Neoplasm Metastasis (Metastasis) 03/2024 - 01/2012
5	Circulating Neoplastic Cells 03/2024 - 01/2019
5	Sepsis (Septicemia) 03/2024 - 10/2021
5	Stroke (Strokes) 01/2024 - 08/2014
5	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2024 - 02/2014
5	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2024 - 02/2014
5	Type 2 Diabetes Mellitus (MODY) 10/2023 - 03/2019
5	Necrosis 10/2023 - 10/2008
5	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2017
5	Ischemia 01/2022 - 01/2008
5	Fibrosis (Cirrhosis) 01/2022 - 01/2013
4	Carcinoma (Carcinomatosis) 01/2024 - 06/2010
4	Necrotizing Enterocolitis 01/2024 - 05/2012
4	Carcinogenesis 01/2024 - 01/2014
4	Glioma (Gliomas) 07/2022 - 09/2019
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 04/2016
3	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 12/2019
3	Esophageal Squamous Cell Carcinoma 01/2023 - 01/2014
3	Pneumonia (Pneumonitis) 01/2023 - 03/2004
3	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 04/2006
3	Leukostasis 08/2018 - 09/2013
3	Burns 01/2018 - 05/2013
3	Retinal Neovascularization 10/2017 - 01/2012
3	Corneal Neovascularization 04/2015 - 05/2013
2	Acute Kidney Injury (Acute Renal Failure) 12/2024 - 01/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 03/2024 - 09/2023
2	Metabolic Bone Diseases (Osteopenia) 03/2024 - 01/2024
2	Cholestasis 03/2024 - 01/2024
2	Anemia 03/2024 - 01/2024
2	Rupture 12/2023 - 01/2021
2	Chronic Disease (Chronic Diseases) 12/2023 - 01/2022
2	Lung Diseases (Lung Disease) 11/2023 - 06/2019
2	Periodontitis 10/2023 - 06/2022
2	Neuroinflammatory Diseases 08/2023 - 08/2018
2	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 01/2014
2	Ischemic Stroke 01/2023 - 08/2014
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2023 - 01/2019

Drug/Important Bio-Agent (IBA)

15	Proteins (Proteins, Gene)FDA Link 04/2024 - 05/2011
11	Biomarkers (Surrogate Marker)IBA 12/2023 - 07/2017
11	Retinaldehyde (Retinal)IBA 01/2020 - 04/2013
9	Oxygen (Dioxygen)IBA 01/2023 - 10/2007
9	Fenofibrate (CiL)FDA LinkGeneric 01/2023 - 09/2013
8	Therapeutic UsesIBA 01/2023 - 09/2013
7	Caffeine (No Doz)FDA LinkGeneric 04/2024 - 01/2021
6	Messenger RNA (mRNA)IBA 03/2024 - 01/2008
6	MicroRNAs (MicroRNA)IBA 01/2024 - 06/2013
6	RNA (Ribonucleic Acid)IBA 01/2023 - 06/2021
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2009
5	CateninsIBA 01/2024 - 01/2014
4	Neuroprotective AgentsIBA 08/2023 - 01/2013
4	Small Interfering RNA (siRNA)IBA 01/2023 - 01/2020
4	Surface-Active Agents (Surfactants)IBA 02/2020 - 02/2014
4	pigment epithelium-derived factorIBA 10/2011 - 12/2009
3	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 06/2013
3	Pulmonary Surfactants (Pulmonary Surfactant)IBA 12/2023 - 04/2019
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2023 - 09/2013
3	Circular RNAIBA 01/2021 - 10/2019
3	caffeine citrate FDA LinkGeneric 01/2021 - 12/2018
3	LipopolysaccharidesIBA 12/2020 - 07/2018
3	salecanIBA 04/2020 - 02/2014
3	AlkaliesIBA 01/2018 - 05/2013
3	PPAR alphaIBA 10/2017 - 05/2014
3	Angiogenesis InhibitorsIBA 01/2012 - 12/2009
2	SteroidsIBA 04/2024 - 01/2021
2	Neoplasm Antigens (Tumor Antigens)IBA 03/2024 - 01/2019
2	AntigensIBA 03/2024 - 01/2021
2	Triglycerides (Triacylglycerol)IBA 03/2024 - 01/2024
2	Antiviral Agents (Antivirals)IBA 03/2024 - 03/2023
2	NF-kappa B (NF-kB)IBA 01/2024 - 04/2019
2	Urea (Carbamide)FDA LinkGeneric 12/2023 - 03/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2023 - 05/2014
2	Erythropoietin FDA Link 08/2023 - 01/2022
2	Transcription Factors (Transcription Factor)IBA 06/2023 - 01/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 05/2023 - 01/2022
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 10/2021
2	Hematoxylin (Haematoxylon)IBA 01/2023 - 08/2016
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2023 - 08/2016
2	NucleotidesIBA 01/2023 - 08/2018

Therapy/Procedure

24	Therapeutics 04/2024 - 03/2004
8	Artificial Respiration (Mechanical Ventilation) 04/2024 - 02/2014
5	Enteral Nutrition (Feeding, Tube) 04/2024 - 01/2022
5	Drug Therapy (Chemotherapy) 01/2024 - 09/2017
4	Immunotherapy 12/2023 - 01/2021
3	Parenteral Nutrition 03/2024 - 01/2023
3	Length of Stay 10/2022 - 04/2019
3	Oral Administration 12/2019 - 04/2010
2	Blood Transfusion (Blood Transfusions) 04/2024 - 03/2024
2	Noninvasive Ventilation 08/2023 - 03/2022